|Mr. Philippe Dubuc M.B.A., MBA||Sr. VP & CFO||430k||N/A||1967|
|Dr. Christian Marsolais||Sr. VP & Chief Medical Officer||441k||N/A||1963|
|Mr. Conor M. Walshe||Gen. Mang. of Theratechnologies Europe Limited||470.79k||N/A||1973|
|Mr. Paul Levesque||Pres, CEO & Director||N/A||N/A||1964|
|Leah Gibson||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Jocelyn Lafond||VP of Legal Affairs & Corp. Sec.||N/A||N/A||1968|
|Mr. Denis Boucher B.A., L.L.B.||VP of Communications & Corp. Affairs||N/A||N/A||1966|
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Inc.’s ISS Governance QualityScore as of December 3, 2020 is 7. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 9; Compensation: 10.